Information regarding trade in Clines share, CLINE B
Cline Scientific AB (publ) ("Cline" or the "Company") have the following information regarding trade in the Company share, CLINE B.
Starting January 18th CLINE B will trade through the auction method introduced this afternoon by Nasdaq for certain stocks on Nasdaq First North Growth Market. According to Nasdaq this aims to assure a better price structure for those stocks with low liquidity and high spread, that is the difference between buy- and sell prices. For more information, please refer to information from Nasdaq via the links below,
IT - Auction Trading semi-annual periodic update (04/24)
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 0703585088
Cline Scientific AB (publ)
Pepparedsleden 1
AstraZeneca BioVentureHub Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.